Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Protocol No

EMN30-64007957MMY3003-MAJESTEC

Staff Member

Binod Dhakal

Phase

III

Summary

This study is being done to see how well 3 different treatment options will work for maintenance treatment for multiple myeloma: Teclistamab given with standard treatment Lenalidomide, Lenalidomide alone, and Teclistamab alone.

Objective

Study of teclistamab combined with lenalidomide for newly diagnosed multiple myeloma patients

Status

OPEN TO ACCRUAL